(19)
(11) EP 2 813 223 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.03.2018 Bulletin 2018/10

(45) Mention of the grant of the patent:
25.10.2017 Bulletin 2017/43

(21) Application number: 14166833.5

(22) Date of filing: 20.11.2007
(51) International Patent Classification (IPC): 
A61K 31/145(2006.01)
A61P 31/00(2006.01)
A61P 9/00(2006.01)
A61K 31/30(2006.01)
A61P 25/00(2006.01)
A61K 31/555(2006.01)
A61K 31/315(2006.01)
A61K 31/28(2006.01)
A61P 35/00(2006.01)
A61K 33/34(2006.01)
A61K 33/30(2006.01)

(54)

Metal delivery agents and therapeutic uses of the same

Metallausgabemittel und therapeutische Verwendungen davon

Agents d'apport métallique et leur utilisation thérapeutique


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 20.11.2006 US 859921 P

(43) Date of publication of application:
17.12.2014 Bulletin 2014/51

(60) Divisional application:
17170883.7 / 3238719

(62) Application number of the earlier application in accordance with Art. 76 EPC:
07815594.2 / 2099441

(73) Proprietor: The University of Melbourne
Parkville, Victoria 3010 (AU)

(72) Inventors:
  • Barnham, Kevin Jeffrey
    Coburg, Victoria 3058 (AU)
  • Donnelly, Paul Stephen
    Carlton, Victoria 3053 (AU)
  • White, Anthony Robert
    Coburg, Victoria 3058 (AU)

(74) Representative: Wills, Andrew Jonathan et al
Mewburn Ellis LLP City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)


(56) References cited: : 
   
  • KOUICHI WADA ET AL: "Cu-ATSM, an Intracellular-Accessible Superoxide Dismutase (SOD)-Like Copper Complex: Evaluation in an Ischemia-Reperfusion Injury Model.", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 17, no. 5, 1 May 1994 (1994-05-01), pages 701-704, XP055148103, ISSN: 0918-6158, DOI: 10.1248/bpb.17.701
  • SAJI H ET AL: "Brain permeable zinc complex with neuroprotective action", S.T.P. PHARMA SCIENCES 199701 FR, vol. 7, no. 1, January 1997 (1997-01), pages 92-97, XP009125608, ISSN: 1157-1489
  • BAYER THOMAS A ET AL: "Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 24, 25 November 2003 (2003-11-25), pages 14187-14192, XP002554797, ISSN: 0027-8424
  • WADA K ET AL: "Copper(II)[2,3-Butanedionebis(N<4>-methyl thiosemicarbazone)], a Stable Superoxide Dismutase-like Copper Complex with High Membrane Penetrability", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, ACADEMIC PRESS, US, vol. 310, no. 1, 1 April 1994 (1994-04-01) , pages 1-5, XP024753015, ISSN: 0003-9861 [retrieved on 1994-04-01]
  • KESSLER H ET AL: "Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease", JOURNAL OF NEURAL TRANSMISSION ; BASIC NEUROSCIENCES, GENETICS AND IMMUNOLOGY, PARKINSON'S DISEASE AND ALLIED CONDITIONS, ALZHEIMER'S DISEASE AND ADOLESCENT PSYCHIATRY RELATED DISORDERS, BIOLOGICAL PSYCHIATRY, BIOLOGICAL CHILD AND ADOLESCENT PSYCHIAT, vol. 113, no. 11, 1 June 2006 (2006-06-01) , pages 1763-1769, XP019444273, ISSN: 1435-1463
  • KUBOTA M ET AL: "Mechanisms of [2,3-butanedione Bis(N4-dimethylthiosemicarbazone)]zinc (Zn-ATSM2)-induced protection of cultured hippocampal neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity", JAPANESE JOURNAL OF PHARMACOLOGY, THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JP, vol. 84, no. 3, 1 January 2000 (2000-01-01), pages 334-338, XP008110964, ISSN: 0021-5198, DOI: 10.1254/JJP.84.334
  • HALLETT P J ET AL: "Rationale for and use of NMDA receptor antagonists in Parkinson's disease", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 102, no. 2, 1 May 2004 (2004-05-01), pages 155-174, XP002699324, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2004.04.001
  • YUETSU IHARA ET AL: "Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 170, no. 2, 1 November 1999 (1999-11-01), pages 90-95, XP055147928, ISSN: 0022-510X, DOI: 10.1016/S0022-510X(99)00192-6
  • PONG KEVIN: "Oxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimetics", EXPERT OPINION ON BIOLOGICAL THERAPY,, vol. 3, no. 1, 1 February 2003 (2003-02-01), pages 127-139, XP009180903, ISSN: 1471-2598
  • EBADI M ET AL: "Ubiquinone (coenzyme Q10) and metallothionein isoforms protect dopaminergic cell lines from apoptosis induced by MPP+ and other inhibitors of mitochondrial complex I", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 26, no. 1-2, 1 January 2000 (2000-01-01), page 579.1, XP009180904, ISSN: 0190-5295
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).